NCT05120830 - NTLA-2002 in Adults With Hereditary Angioedema (HAE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

April 4, 2024

Study Completion Date

March 31, 2026

Conditions

Hereditary Angioedema

Interventions

BIOLOGICAL

Biological NTLA-2002

CRISPR/Cas9 gene editing system delivered by LNP for IV administration

OTHER

Normal Saline IV Administration

The administration of IV normal saline

Trial Locations (9)

Clinical Trial Site, Campbelltown

Clinical Trial Site, Grenoble

Clinical Trial Site, Lille

Clinical Trial Site, Paris

Clinical Trial Site, Berlin

Clinical Trial Site, Frankfurt

Clinical Trial Site, Amsterdam

Clinical Trial Site, Auckland

Clinical Trial Site, Cambridge